Phase 1 Vitiligo Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 75 years old (at the time of the screening appointment)
- People who have been confirmed by the study doctor to have non-segmental vitiligo (a type of vitiligo that appears in patches on both sides of the body) at both the screening and baseline visits
- People who, if taking any other medications for reasons unrelated to vitiligo, have been on a stable dose for a set period before the study starts and are willing to keep that regimen unchanged throughout the study
- Note: There are additional inclusion criteria not listed here — the study centre will check if you meet all of them
Who may not be able to join:
- People who currently have other active skin conditions that cause loss of skin colour or pigmentation (such as certain genetic disorders, age-related skin changes, or pigmentation loss caused by medications or chemicals)
- People who currently have other active inflammatory skin conditions (such as psoriasis, discoid lupus, or leprosy) that, in the study doctor's opinion, could interfere with evaluating the vitiligo or the treatment
- People where more than roughly one-third of the hairs in the vitiligo-affected areas on their face have lost their colour, as assessed by a healthcare professional at screening
- Note: There are additional exclusion criteria not listed here — the study centre will check if you meet all of them
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
+61 2 8651 2042
+61 2 4058 5486
+61 7 3397 3200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102; Percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI); Number of participants with percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.